BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $15.17.

Several equities analysts have recently issued reports on BCRX shares. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BCRX. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares during the period. KBC Group NV boosted its stake in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth about $82,000. Finally, DRW Securities LLC acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $74,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 1.1 %

Shares of BCRX opened at $8.02 on Thursday. The company has a 50 day moving average of $7.62 and a two-hundred day moving average of $7.68. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -13.15 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period in the previous year, the business earned ($0.19) EPS. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.